Recursion Pharmaceuticals Awards Director Stock Package Amid AI Drug Discovery Push

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Namandje Bumpus received new equity compensation grants on June 18, 2025, consisting of:

• 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
• 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs

Following these transactions, Bumpus directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation rather than open market transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bumpus Namandje

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,016	$0.00	--
Grant/Award	Class A Common Stock	11,008	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,016 shares (Direct); Class A Common Stock — 47,557 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bumpus Namandje

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/18/2025		A(1)		11,008	A	$0	47,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.11	06/18/2025		A		22,016		(2)	06/18/2035	Class A Common Stock	22,016	$0	22,016	D

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at RXRX on June 18, 2025?

Director Namandje Bumpus received two equity grants: 11,008 restricted stock units (RSUs) and stock options to purchase 22,016 shares of Class A Common Stock at an exercise price of $5.11 per share. These grants were made pursuant to the company's Outside Director Compensation Policy.

When do Namandje Bumpus's RXRX stock options and RSUs vest?

Both the RSUs and stock options will vest on the earlier of June 18, 2026, or the day prior to Recursion Pharmaceuticals' 2026 Annual Meeting of Stockholders, subject to the director's continued service to the company.

How many shares of RXRX does Namandje Bumpus own after the June 2025 grants?

Following the transactions, Bumpus directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. All holdings are listed as Direct (D) ownership.

What is the exercise price and expiration date of RXRX stock options granted to Bumpus?

The stock options were granted with an exercise price of $5.11 per share and expire on June 18, 2035, ten years from the grant date.

Was this RXRX insider transaction made under a 10b5-1 trading plan?

No, the Form 4 filing does not indicate that these grants were made pursuant to a Rule 10b5-1 trading plan. These appear to be standard director compensation grants made under the company's Outside Director Compensation Policy.